References
- Kaufmann, S. H. : Induction of endonucleolytic DNA cleavagein human acute myelogenous leukemia cells by etoposide, camptoyhecin, and other cytotoxic anticancer drugs : acautionary note. Cancer Res. 49, 5870 (1989)
- Barry, M. A., Behnke, C. A. and Eastman, A. : Activation of programmed cell death (apoptosis) by cisplatin, other anti-cancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40, 2353 (1990) https://doi.org/10.1016/0006-2952(90)90733-2
- O'Connor, P. M., Wastermann, K., Sarang, M., Magrath, I., Bohr, V. A. and Kohn,K W. : Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res. 51, 6550 (1991)
- Miyashita, T. and Reed, J. C. : Blood 81, 151 (1993)
- Kim, D.-K., Kim, C., Gam,J., Cho, Y.-B., Hong, w.-S. and Park, J.-G. : J Medicinal Chemistry 37, 1471 (1994)
- Loehrer, P. J. and Einhorn, L. H. : Drugs five years later. cisplatin. Ann. Inter. Med. 100, 704 (1984)
- Ozols, R. E. and Young, R. C. : Chemotherapy of ovarian cancer. Semin. Oncol. 11, 251 (1984)
- Fiorentino, M. V. and Ghiotto, C. : Platinum, the synergistic drug, from clinical evidence to laboratory suggestions. in platinum and other metal coordination compounds in cancer chemotherapy;Nicolini, M., Ed., Martinus Nijhoff Publishing. Boston 415 (1988)
- Choksi, A. and Hong, W. K : Chemotherapy of head and neck cnacer. Boston 375 (1988)
- Paccagnella, A., Favaretto, G. and Fiorentino, M. V. : Chem-otherapy of lung cnacer. Boston 394 (1988)
- Wagener, D. J., Yap, S. H., Wobbes, T., Burghouts, J. T., van Dam, F E., Hillem, H. E, Hoogendooorn, G. J., Scheerder, H. and van der Vert, S. G. : Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer.Cancer Chemother. Pharmacol. 15, 86 (1985)
- Prestayko, A. w., Crooke, S. T. and Carter, S. K, Eds. : Academic Press. Ins.New York, 317 (1980)
- Von Hoff, D. D., Schilsky, R, Reichert, C. M., Reddick, R. L., Rozencweig, M., Young, R C. and Muggia, F. M. : Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat. Rep. 63, 1527 (1979)
- Krakoff, I. H. : Nephrotoxicity of cis-dichlorodiammine-platinum (II). Cancer Treat. Rep. 63, 1523 (1979)
- Iahibiki, K, Kumai, K., Kodaira, S., Abe, O., Yamamoto, K., Oodchi, T., Fukaya,Y., Kimura, K., Takamatsu, K., Ootsuka, E., Sakabe, T., Nishiyama, K., Sekizawa, Y., Ooide, N., Tsuchiya, S., Togo, S., Ishida, T., Mishima, Y., Ogoshi, K and Mitomi., T. : Phase II study with cisplatin in dvanced stomach and colon carcinoma. Jpn. J Cancer Chemother. 16, 3185 (1989).
- Hong, W. S., Saijo, N., Sasaki, Y., Minato, K., Nakano, H., Nakagawa, K., Fujiwara, Y., Nomura, K. and Twentyman, P. R. : Establishment and characterization of cisplatin-resistant sub-lines of human lung cancer lines. Int. J. Cancer 41, 462 (1988)
- Inoue, K., Mukaiyama, T., Mitsui, I. and Ogawa, M. : In vitro evaluation of anticancer drugs in relation to development of drug resistance in the human tumor clonogenic assay. Cancer Chemother. Pharmacol. 15, 208 (1985)
- Ozols, R. E : Pharmacologic rebersal of drug resistance in ovarian cancer. Semin. Oncol. 12, 7 (1985)
- Kim, D. K., Kim, H. T., Cho, Y. B., Tai, T. H., Ahn, J. S., Kim, T. S., Kim, K. H. and Hong, W. S. : Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminome-thyl)-2-isopropy1-1,3-dioxolane]platinum (II), a new platinum analogue, as an anticancer agent. Cancer Chemother Pharmacl. 35, 441 (1995). https://doi.org/10.1007/s002800050260
- Glotzer, M. : Cyclin is degraded by the ubiquitin pathway. Nature 349, 132 (1991) https://doi.org/10.1038/349132a0